LLY (NYSE) - Eli Lilly and Company | Stock Price & Analysis

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5324571083
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Web URL: https://www.lilly.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for LLY (NYSE) - Eli Lilly and Company | Stock Price & Analysis


Market Cap in USD 579,856m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1978-01-13


Fundamental 5.18
Dividend 8.24
Performance 5y 9.20
Rel. Performance vs Sector 2.66
Analysts 4.14
Fair Price Total Ret. 727.99
Fair Price DCF todo


Growth TTM 61.17%
CAGR 5y 40.06%
CAGR / Mean Drawdown 6.32
Sharpe Ratio TTM 1.95
Alpha vs SP500 TTM 50.73
Beta vs SP500 5y weekly 0.61
CAPM 6.91%
Average Daily Range 2m 2.91%
Reversal Oscillator 33.57
Volatility GJR Garch 1y 26.03%
Price / SMA 50 2.14%
Price / SMA 200 26.12%
Current Volume 2436.7k
Average Volume 20d 3472.3k


Yield TTM 0.76%
Yield on Cost 5y 4.13%
Dividends CAGR 5y 11.74%
Consistency of Dividends all time 99.7%